Enhanced Immune Response to Rabies Viruses by the Use of a Liposome Adjuvant in Vaccines.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Source:
      Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 8801552 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8976 (Electronic) Linking ISSN: 08828245 NLM ISO Abbreviation: Viral Immunol Subsets: MEDLINE
    • Publication Information:
      Original Publication: New York, NY : Mary Ann Liebert, Inc., c1987-
    • Subject Terms:
    • Abstract:
      Essen regimen, the Thai Red Cross two-site ID regimen, Zagreb schedule, and the eight-site ID regimen are the standard rabies vaccines recommended by the World Health Organization (WHO). In this study, a liposomal rabies vaccine (LipoRV) was developed, which was found to facilitate the production of rabies virus neutralizing antibody (RVNA) in BALB/c mice. Liposome solution was prepared with hydrogenated soya phosphatide and cholesterol. LipoRV composed of liposome solution and inactivated rabies vaccine (IRV). The immune responses were compared between the mice treated with either LipoRV or IRV. Higher levels of interleukin-2 (p < 0.05), interferon-γ (p < 0.01), and natural killer cell activity (p < 0.05) were observed in the mice immunized with LipoRV than those with IRV. The potency of LipoRV was significantly higher than that IRV (p < 0.05). In addition, three injections of LipoRV on days 0, 3, and 14 could elicit similar RVNA levels as the five shots of IRV. Our data also showed a higher survival rate in mice treated with three shots of LipoRV (56.2%) than five shots of IRV (40.6%). In conclusion, liposome enhances the immune response of mice to rabies vaccine and could be applied as a potential immunopotentiator.
    • Contributed Indexing:
      Keywords: immune response*; liposomal rabies vaccine*; liposome*; rabies vaccine*
    • Accession Number:
      0 (Adjuvants, Immunologic)
      0 (Antibodies, Neutralizing)
      0 (Antibodies, Viral)
      0 (Cytokines)
      0 (Liposomes)
      0 (Rabies Vaccines)
    • Publication Date:
      Date Created: 20170928 Date Completed: 20180810 Latest Revision: 20191210
    • Publication Date:
      20220302
    • Accession Number:
      10.1089/vim.2017.0093
    • Accession Number:
      28953450